Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-22
2010-06-22
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S455000, C536S023100, C536S024310, C536S024500
Reexamination Certificate
active
07741306
ABSTRACT:
Naturally occurring miRNAs that regulate human oncogenes and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA ,or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The compositions are administered to a subject prior to administration of a cytotoxic therapy in an amount effective to sensitize cells or tissues to be treated to the effects of the cytotoxic therapy.
REFERENCES:
patent: 3832253 (1974-08-01), Di Palma et al.
patent: 3854480 (1974-12-01), Zaffaroni
patent: 4452775 (1984-06-01), Kent
patent: 4667013 (1987-05-01), Reichle
patent: 4675189 (1987-06-01), Kent et al.
patent: 4748034 (1988-05-01), de Rham
patent: 5075109 (1991-12-01), Tice et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5239660 (1993-08-01), Ooi
patent: 5272071 (1993-12-01), Chappel
patent: 5378825 (1995-01-01), Cook et al.
patent: 5407686 (1995-04-01), Patel et al.
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5578461 (1996-11-01), Sherwin et al.
patent: 5602240 (1997-02-01), De Mesmaeker et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5614617 (1997-03-01), Cook et al.
patent: 5672697 (1997-09-01), Buhr et al.
patent: 5705629 (1998-01-01), Bhongle
patent: 5714606 (1998-02-01), Acevedo et al.
patent: 5736152 (1998-04-01), Dunn
patent: 5777092 (1998-07-01), Cook et al.
patent: 5858988 (1999-01-01), Wang
patent: 6919208 (2005-07-01), Levy et al.
patent: 2005/0227256 (2005-10-01), Hutvagner et al.
patent: 2006/0141600 (2006-06-01), Joshua-Tor et al.
patent: 2008/0182245 (2008-07-01), Brown et al.
patent: WO 84/03564 (1984-09-01), None
patent: WO 91/06667 (1991-05-01), None
patent: WO 91/09955 (1991-07-01), None
patent: WO 92/20808 (1992-11-01), None
patent: WO 93/09222 (1993-05-01), None
patent: WO 94/12650 (1994-06-01), None
patent: WO 94/28122 (1994-12-01), None
patent: WO 2004/076622 (2004-09-01), None
Crooke, S.T., Annu. Rev. Med., vol. 55, pp. 61-95 (2004).
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Chirila, T. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Opalinska, J.B. et al., Nature Reviews, vol. 1, pp. 503-514 (2002).
Branch, A. Trends, in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Agrawal, et al., “Antisense therapeutics: is it as simple as complementary base recognition?”,Molecular Med. Today, 6(2):72-81 (2000).
Branch, “A good antisense molecule is hard to find”,Trends in Biochem. Sci., 23(2):45-50 (1998).
Chirila, “The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides”,Biomaterials, 23(2):321-342 (2002).
Crooke, “Antisense Research and Application”, Chapter 1, pp. 1-50 (Ed. By S. Crooke). Springer-Verlag (1998).
Opalinska, “Nucleic-acid therapeutics: basic principles and recent applications”,Nature Rev. Drug Discov., 1(7):503-514 (2002).
Peracchi, “Prospects for antiviral ribozymes and deoxyribozymes”,Rev. Med. Virol., 14(1):47-64 (2004).
Abrahante, et al., “TheCaenorhabditis eleganshunchback-like gene lin-57/hbl-1 controls developmental time and is regulated by microRNAs”,Dev Cell, 4(5):625-637 (2003).
Ahrendt, et al., “Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung”,Cancer, 92:1525-1530 (2001).
Akao, et al., “let-7 microRNA functions as a potential growth suppressor in human colon cancer cells”,Biol. Pharm. Bull., 29(5):903-6 (2006).
Ambros, “Cell cycle-dependent sequencing of cell fate decisions inCaenorhabditis elegansvulva precursor cells”,Development, 126:1947-1956 (1999).
Ambros and Horvitz, “Heterochronic mutants of the nematodeCaenorhabditis elegans”, Science, 226:409-416 (1984).
Antebi, “The tick-tock of aging?”, Science, 310:1911-1913 (2005).
Baker and Sanger, “The density of clonogenic cells in human solid tumors”,Int. J. Cell Cloning, 9(2):155-65 (1991).
Banerjee and Slack, “Control of developmental timing by small temporal RNAs: a paradigm for RNA-mediated regulation of gene expression”,Bioessays, 24(2):119-29 (2002).
Bartel, “MicroRNAs: Genomics, Biogenesis, Mechanism, and Function”,Cell, 116(2):281-97 (2004).
Beitel, et al., “Caenorhabditis elegansras gene let-60 acts as a switch in the pathway of vulval induction”,Nature, 348(6301):503-509 (1990).
Berset, et al., “Notch inhibition of RAS signaling through MAP kinase phosphatase LlP-1 duringC. elegansvulval development”,Science, 291:1055-1058 (2001).
Boehm and Slack, “A developmental timing microRNA and its target regulate life span inC. elegans”, Science, 310:1954-1957 (2005).
Brennecke, et al., “Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid inDrosophila”,Cell, 113(1):25-36 (2003).
Brenner, “The genetics ofCaenorhabditis elegans”, Genetics, 77(1):71-94 (1974).
Brown and Wilson, “Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us?”,Cancer Biol. Ther., 2(5):477-90 (2003).
Brummelkamp, et al., “Stable suppression of tumorigenicity by virus-mediated RNA interference”,Cancer Cell, 2(3):243-7 (2002).
Calin, et al., “Human microRNA gene are frequently located at fragile sites and genomic regions involved in cancers”,Proc Natl Acad Sci U S A, 101:2999-3004 (2004).
Calin, et al., “Frequent deletions and doenregulation of microRNA genesmiR15 andmiR16 at 13q14 in chronic lymphocytic leukemia”,Proc Natl Acad Sci U S A, 99(24):15524-9 (2002).
Capecchi, “Altering the genome by homologous recombination”,Science, 244:1288-1292 (1989).
Carmell, et al., “The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis”,Genes Dev., 16(21):2733-42 (2002).
Caudy, et al., “A micrococcal nuclease homologue in RNAi effector complexes”,Nature, 425(6956):411-4 (2003).
Ceol and Horvitz, “A new class ofC. eleganssynMuv genes implicates a Tip60/NuA4-like HAT complex as a negative regulator of Ras signaling”,Dev Cell, 6:563-576 (2004).
Chang, et al., “MicroRNAs act sequentially and asymmetrically to control chemosensory laterality in the nematode”,Nature, 430(7001):785-9 (2004).
Chen, et al., “The developmental miRNA profiles of zebrafish as determined by small RNA cloning”,Genes Dev., 19(11):1288-93 (2005).
Chen, et al., “MicroRNAs Modulate HematopoieticLineage Differentiation”,Science, 303(5654):83-6 (2004).
Dent and Han, “Post-embryonic expression pattern ofC. elegans let-60 rasreporter constructs”,Mech Dev, 72:179-182 (1998).
Duursma and Agami, “Ras interference as cancer therapy”,Semin. Cancer Biol., 13(4):267-73 (2003).
Eisenmann and Kim, “Mechanism of activation of theCaenorhabditis elegansras homologue let-60 by a novel, temperature-sensitive, gain-of-function mutation”,Genetics, 146:553-565 (1997).
Esquela-Kerscher, et al., “Post-embryonic expression ofC. elegansmicroRNAs belonging to the lin-4 and let-7 families in the hypodermis and the reproductive system”,Dev. Dyn., 234(4):868-77 (2005).
Feinbaum and Ambros, “The timing of lin-4 RNA accumulation controls the timing of postembryonic developmental events inCaenorhabditis elegans”, Dev Biol, 210(1):87-95 (1999).
Freemont, “The Ring finger. A novel protein sequence motif related to the zinc finger”,An
Grosshans Helge
Johnson Steven M.
Slack Frank J.
Weidhaas Joanne Barnes
Elrifi, Esq. Ivor R.
Miller Katherine J.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Yale University
Zara Jane
LandOfFree
Regulation of oncogenes by microRNAs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of oncogenes by microRNAs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of oncogenes by microRNAs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208312